Nasdaq halts trading of Exact Sciences' stock; Neovasc raises $22.5M to help propel development of cardiac implants;

@FierceMedDev: Baxter will keep its sprawling medical products arm and spin off its biopharmaceuticals into a separate company. More | Follow @FierceMedDev

@MarkHFierce: Zyomyx grabs some funding to launch its HIV/AIDS test in emerging markets. More via FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. Article via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Supercomputer from "Jeopardy" game show will help scientists read mutations, find drug cocktail for cancer. Story via New York Times | Follow @EmilyWFierce

> Nasdaq has halted trading of Exact Sciences ($EXAS) stock, even as the company meets with an FDA panel of experts on March 27 to discuss a PMA application for its stool DNA-based non-invasive colorectal cancer-screening test. Release

> Guided Therapeutics wants to meet with the FDA within the next two to three months to talk about a PMA approval pathway for its cervical scan diagnostic device. Release

> Vasomedical, a New York maker of medical devices and diagnostic imaging products, said it boosted revenue and reduced net losses in 2013. Release

> California's ArtVentive Medical Group is rolling out a new catheter-assisted endovascular tumor treatment system. Release

> Canada's Neovasc has raised $22.5 million in new equity funding, money that will be used, in part, to help propel development of its cardiac implants. Story

> After three FDA rejections, partners Alimera Sciences ($ALIM) and pSivida ($PSDV) are again submitting their drug-device combo for approval. More

Biotech News

@FierceBiotech: ICYMI: GlaxoSmithKline joins a biotech brain trust to make R&D more efficient. News | Follow @FierceBiotech

@JohnCFierce: I'll be curious to see how Novartis does with the early application on 'breakthrough' drug. Looks promising. Story | Follow @JohnCFierce

@DamianFierce: Brief on $BAX's breakup: creates a $6B biopharma player with focus on bleeding disorders, immune deficiencies. More | Follow @DamianFierce

@EmilyMFierce: Antioxidant could slow progression of Lou Gehrig's disease, extend lifespan. News | Follow @EmilyMFierce

> Exelixis' shares flogged after lead drug disappoints at interim PhIII point. More

> RuiYi banks $15M from A-list backers to amp up Chinese R&D. Article

Pharma News

@FiercePharma: Colorado vaccine bill: Necessary education or treating parents like 'idiots'? - Fierce Vaccines. Story | Follow @FiercePharma

@TracyStaton: Anti-inflammatories rule! Top 3 best-selling drugs last year = Humira, Enbrel + Remicade. More | Follow @TracyStaton

@EricPFierce: FDA 's Woodcock throws cold water on research that found foreign-made generics of Lipitor tainted. News | Follow @EricPFierce

@CarlyHFierce: ICYMI, here's that link again to yesterday's full issue of FiercePharmaMarketing. It includes a walking bladder. More | Follow @CarlyHFierce

> Drugmakers agree to new FDA rules restricting antibiotic use in livestock. Article

> Worried about legal jeopardy, Merck, GlaxoSmithKline halt copay help for Obamacare patients. News

> New NICE evals could green-light more drugs, but only at 'the very best price.' Story

Pharma Manufacturing News

> Baxter, FDA scramble to overcome shortage of nitroglycerin. News

> GSK says someone tampered with alli bottles. News

> FDA takes aim at yet another Indian API maker. Story

> Market force may put quality at forefront of all generics makers. Article

> FDA's Woodcock throws cold water on generic drug research. Story

> French CMO Novacep sees growth. Brief

Vaccines News

> 'Breakthrough' nod for Pfizer MenB candidate sets up showdown with Bexsero. Story

> PhIII fail further dents hopes for GSK's cancer vaccine. Story

> Colorado vaccine bill: Necessary education or treating parents like 'idiots'? Article

> Novartis' Bexsero wins U.K. recommendation in government U-turn. News

> Government H5N1 vaccine orders drive jump in sales at Sinovac. Story

> Buzz: Baxter is considering selling its vaccine unit. Brief

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.